KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash & Current Investments (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Cash & Current Investments data on record, last reported at $270.2 million in Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 10.52% year-over-year to $270.2 million; the TTM value through Sep 2025 reached $270.2 million, up 10.52%, while the annual FY2024 figure was $255.2 million, 15.94% down from the prior year.
  • Cash & Current Investments reached $270.2 million in Q3 2025 per NKTR's latest filing, up from $175.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $1.0 billion in Q1 2021 and bottomed at $175.9 million in Q2 2025.
  • Average Cash & Current Investments over 5 years is $489.3 million, with a median of $409.4 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: plummeted 40.68% in 2022, then increased 10.52% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $734.0 million in 2021, then plummeted by 31.2% to $505.0 million in 2022, then tumbled by 39.88% to $303.6 million in 2023, then decreased by 15.94% to $255.2 million in 2024, then rose by 5.87% to $270.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $270.2 million in Q3 2025, $175.9 million in Q2 2025, and $218.6 million in Q1 2025.